Fennec Pharmaceuticals (FRX) Set to Announce Earnings on Thursday

Fennec Pharmaceuticals (TSE:FRX) is scheduled to be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of C($0.19) per share for the quarter.

Fennec Pharmaceuticals (TSE:FRX) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing the consensus estimate of C$0.08 by C($0.35). The firm had revenue of C$9.94 million during the quarter, compared to analyst estimates of C$18.67 million. Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%.

Fennec Pharmaceuticals Trading Up 11.5 %

FRX stock traded up C$0.70 during midday trading on Tuesday, reaching C$6.78. 1,060 shares of the company’s stock traded hands, compared to its average volume of 1,814. Fennec Pharmaceuticals has a fifty-two week low of C$5.76 and a fifty-two week high of C$15.43. The business has a 50-day moving average price of C$6.72 and a two-hundred day moving average price of C$8.56. The company has a market capitalization of C$185.50 million, a P/E ratio of 60.80 and a beta of 0.25. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.